Bladder cancer drug combo trial pulled before it even started
NCT ID NCT05564416
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 35 times
Summary
This trial was designed to test two drugs—erdafitinib and atezolizumab—for people with muscle invasive bladder cancer who cannot take the standard chemotherapy drug cisplatin. Erdafitinib targets a specific gene change that can drive cancer growth, while atezolizumab helps the immune system attack cancer cells. The study was withdrawn before any patients were enrolled, so no data were collected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III BLADDER CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
erdafitinib and atezolizumab
What this could lead to
If successful, this could point toward a new treatment option for bladder cancer patients who cannot receive standard chemotherapy.
What could go wrong
The trial was withdrawn before enrolling any participants, so no results are available. It is unclear if the approach would be effective or safe.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.